Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

View basket
☰

Bempedoic Acid

Bempedoic Acid
In stock
180mg
from 42,04 £
Strength
Pack size — the bigger the pack, the cheaper the tablet
50,45 £42,04 £
1,40 £ per tablet

In brief

  • Bempedoic acid (Nilemdo; with ezetimibe, Nustendi) is a prescription-only medicine in the UK and should not be supplied without a valid prescription.
  • Bempedoic acid is used to lower LDL‑cholesterol in adults (as an adjunct to diet and maximally tolerated statin therapy or for statin‑intolerant patients); it works by inhibiting ATP citrate lyase (ACL), reducing cholesterol synthesis upstream of the HMG‑CoA reductase step targeted by statins.
  • The usual dose is 180 mg orally once daily for monotherapy; the fixed‑dose combination with ezetimibe is 180 mg/10 mg once daily.
  • The medicine is supplied as film‑coated tablets for oral administration, taken once daily, with or without food.
  • Effects on LDL‑cholesterol begin to appear within 2–4 weeks, with clinical reassessment typically at 4–12 weeks to judge response.
  • The pharmacological effect is sustained with daily dosing (duration of action per dose is approximately 24 hours), and LDL‑lowering is maintained only while treatment continues.
  • There is no specific prohibition on moderate alcohol use, but avoid excessive alcohol—particularly if you have liver disease or elevated hepatic enzymes—and discuss alcohol intake with your prescriber.
  • The most common side effect is increased blood uric acid (hyperuricaemia), which may precipitate gout; other frequent adverse effects include muscle spasms, back or limb pain, upper respiratory infection, gastrointestinal complaints and elevated liver enzymes.
  • Would you like to try bempedoic acid without a prescription?

Basic bempedoic acid information

  • INN (international nonproprietary name): Bempedoic acid
  • Brand names available in the United Kingdom: Nilemdo (bempedoic acid 180 mg), Nustendi (bempedoic acid 180 mg/ezetimibe 10 mg)
  • ATC code: C10AX15
  • Forms and dosages: Film-coated tablet 180 mg (monotherapy); film-coated tablet 180 mg/10 mg (fixed combination with ezetimibe)
  • Manufacturers in the United Kingdom: Daiichi Sankyo (Nilemdo, Nustendi)
  • Registration status in the United Kingdom: Prescription-only medicine (POM)
  • OTC / Rx classification: Prescription only (Rx)

Critical warnings and restrictions

Are you worried this medicine could harm someone in your household?

Bempedoic acid is a prescription-only medicine and should only be used under a prescriber’s supervision.

Pregnancy and breastfeeding are absolute contraindications for bempedoic acid because safety data are lacking and potential fetal or neonatal risk cannot be ruled out.

Women of childbearing potential must use effective contraception while taking bempedoic acid and should have a pregnancy test if pregnancy is possible before starting therapy.

Severe renal impairment (eGFR <30 mL/min/1.73 m²) and severe hepatic impairment are situations where bempedoic acid is not recommended or requires strong caution due to limited data.

There is a documented risk of increased serum uric acid and hyperuricaemia with bempedoic acid, so check history of gout before prescribing.

Tendon disorders, including tendon rupture, have been reported with drugs that affect tendons; review any history of tendon rupture or disorders before starting treatment.

Elderly patients need monitoring for adverse effects, but routine dose reduction is not required by available data.

Use the checklist below to protect immediate patient safety before initiation.

  • Pregnancy test if pregnancy possible.
  • Baseline liver function tests (LFTs).
  • Baseline renal function (eGFR).
  • Baseline serum uric acid.
  • Review concomitant medications for gout risk and tendon risk.

Checklist for baseline tests

  • Full blood count not routinely required unless clinically indicated.
  • Liver function tests: ALT, AST and bilirubin before starting and repeated if clinically indicated.
  • Serum creatinine/eGFR prior to initiation and periodically in those with impaired renal function.
  • Serum uric acid baseline and if symptomatic during therapy.
  • Pregnancy test for women of childbearing potential.
Contraindication Clinical note
Known hypersensitivity to bempedoic acid or excipients Avoid use; document allergy in records
Pregnancy Contraindicated; advise effective contraception
Breastfeeding Contraindicated; advise to stop breastfeeding if treatment necessary
Severe hepatic impairment Not recommended; consider alternatives
Severe renal impairment (eGFR <30) Use caution; limited data available

Interaction with activities (driving and workplace safety)

Concerned about how the tablets will affect your day‑to‑day tasks?

Some patients report fatigue, muscle pains or dizziness while taking bempedoic acid.

Advise patients not to operate heavy machinery or drive until they know how the medicine affects them.

Record counselling about activity precautions in the patient’s GP or non-medical prescriber (NMP) record.

Q&A — Can I drive after taking it in the UK?

Usually yes, but stop driving if you experience dizziness, extreme fatigue or severe muscle symptoms.

Report worrying symptoms to your GP or pharmacist and follow DVLA guidance on fitness to drive.

Usage basics — names, legal status, UK availability

Who makes this tablet and what is it called in the UK?

The international nonproprietary name (INN) is bempedoic acid.

In the UK the licensed brand name is Nilemdo (bempedoic acid 180 mg) and the fixed combination with ezetimibe is marketed as Nustendi (bempedoic acid 180 mg/ezetimibe 10 mg).

The originator is Esperion Therapeutics, and Daiichi Sankyo markets Nilemdo and Nustendi in the UK.

Legal classification and how you get it

Bempedoic acid is a prescription-only medicine (POM) in the UK.

Supply in the UK is via NHS prescriptions or private prescribers and dispensed through community pharmacies.

INN
International Nonproprietary Name — common name for the active substance (bempedoic acid).
POM
Prescription-only medicine — requires a prescriber’s prescription.
Fixed-dose combination
A single tablet containing two active ingredients, for example bempedoic acid plus ezetimibe (Nustendi).
Brand Pack/strength Manufacturer
Nilemdo 180 mg tablets, blister Daiichi Sankyo Europe
Nustendi 180 mg/10 mg tablets Daiichi Sankyo Europe

Dosing guide — NHS-aligned regimens and adjustments

What dose will the GP usually start you on?

The standard adult dose is 180 mg orally once daily as a film-coated tablet.

When supplied as a fixed-dose combination with ezetimibe the dose is 180 mg/10 mg once daily.

Tablets may be taken with or without food.

Clinicians should reassess LDL‑C and tolerability at about 4–12 weeks after starting treatment.

Adjustments for comorbidities

No routine dose change is required for elderly patients based on available data.

No adjustment is required for mild or moderate renal impairment (eGFR ≥30 mL/min/1.73 m²), but caution is advised in severe renal impairment due to limited data.

Use caution and monitor in moderate hepatic impairment; the drug is not recommended in severe hepatic impairment.

Not approved for paediatric use.

Q&A — What if I miss a dose?

Take the missed dose as soon as you remember unless it is almost time for the next dose.

Do not double up doses to make up for a missed one.

If in doubt, contact your GP or pharmacist for advice.

  • Checklist for baseline tests: LFTs, renal function (eGFR), serum uric acid, pregnancy test if applicable.
  • Monitoring schedule: LDL‑C reassessment at 4–12 weeks; periodic LFTs if clinically indicated; monitor uric acid if history of gout; record adverse events promptly.

Interaction chart — food, drink and drug conflicts

Can you take the tablets with your favourite foods and drinks?

No specific food interactions are required; tablets can be taken with or without food.

Advise moderation of alcohol because alcohol can raise uric acid and may worsen hyperuricaemia associated with bempedoic acid.

Give simple dietary advice alongside therapy, such as reduced saturated fat, increased fibre and weight management to help lower LDL‑C.

Common drug conflicts and practical actions

Concomitant drug/food Practical action Monitoring required
Diuretics that raise uric acid Review necessity; consider alternatives if recurrent gout Serum uric acid and gout symptom review
Drugs associated with tendon rupture (e.g. fluoroquinolones) Avoid co-prescription where possible; counsel on tendon symptoms Monitor for tendon pain, swelling or rupture
Agents that alter hepatic function Assess liver enzyme risks; avoid if severe hepatic impairment Baseline and periodic LFTs if indicated

Report suspected adverse drug reactions to the MHRA Yellow Card scheme and document events in the clinical record.

Legal status and availability in the UK

In our online pharmacy, bempedoic acid is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Mechanism and pharmacology — plain English and clinical terms

Why does bempedoic acid lower cholesterol?

Bempedoic acid inhibits ATP citrate lyase (ACL), an enzyme upstream of HMG‑CoA reductase in the cholesterol synthesis pathway.

By reducing hepatic cholesterol synthesis it lowers low‑density lipoprotein cholesterol (LDL‑C).

The drug is activated in the liver and not in skeletal muscle, a factor that may explain a different muscle side‑effect profile compared with statins.

ACL inhibitor
Blocks ATP citrate lyase to reduce cholesterol synthesis in the liver.
LDL‑C
Low‑density lipoprotein cholesterol — the main target for cardiovascular risk reduction.
Activation site
Bempedoic acid is a prodrug activated mainly in the liver, not in muscle tissue.

Clinical terms and pharmacokinetics

The ATC code is C10AX15, classed as an other lipid‑modifying agent.

The usual formulation is a once‑daily oral 180 mg film‑coated tablet with a fixed‑dose combo available with ezetimibe for added LDL‑C lowering.

Indications and off‑label uses — MHRA stance vs practice

What is this tablet officially for?

Authorised indications include primary hypercholesterolaemia and mixed dyslipidaemia as an adjunct to diet and to maximally tolerated statin therapy, or for patients who are statin‑intolerant.

The standard adult dose is 180 mg once daily and the fixed combination with ezetimibe provides greater LDL‑C reduction.

Off‑label practices

Specialist lipid clinics may use bempedoic acid in tailored regimens or in complex patients where evidence supports its use, but off‑label prescribing requires governance.

  • Approved indications: Primary hypercholesterolaemia, mixed dyslipidaemia as add‑on to diet and statin therapy or as option for statin intolerance.
  • Off‑label considerations: Use in specialist settings with documented evidence, informed consent and enhanced monitoring; paediatric use is not recommended.

Checklist for clinicians considering off‑label prescribing: document evidence base, obtain informed consent, set monitoring timetable, and record rationale in notes.

Alternatives matrix — NHS prescribing options

What else might the GP prescribe instead of—or in addition to—bempedoic acid?

Drug class Typical LDL‑C reduction Route Availability Suitability
Statins (atorvastatin, rosuvastatin) Large (varies by dose) Oral Widely available on NHS First‑line for most patients
Ezetimibe Modest when alone; additive with statin Oral NHS available Good for statin add‑on or intolerance
PCSK9 inhibitors (alirocumab, evolocumab) Very large Subcutaneous injection Specialist referral Reserved for very high‑risk or specialist use

Pros and cons checklist

  • Pros of bempedoic acid: oral dosing, additive LDL‑C lowering, option for some statin‑intolerant patients.
  • Cons of bempedoic acid: raises uric acid, tendon risk concerns, prescription-only and monitoring needs.
  • Consider patient preference and monitoring burden when choosing therapy.

Common questions from UK patients

Patients usually want quick, clear answers at the pharmacy counter.

  • Q: How quickly will my cholesterol fall?

    A: LDL‑C is typically reassessed at 4–12 weeks and the magnitude of reduction depends on baseline therapy and combination use.
  • Q: Can I take it with my statin?

    A: Yes — it is licensed as an add‑on to maximally tolerated statin therapy; monitor for muscle symptoms and LFT changes.
  • Q: Will it cause muscle damage like statins?

    A: It has a different activation profile, being activated mainly in the liver rather than muscle, but muscle events have been reported so monitor and report any myopathy.
  • Q: Is it safe with gout?

    A: Bempedoic acid can raise serum uric acid, so use caution and consider alternatives for patients with recurrent gout.

Registration and regulation — MHRA and prescribing framework

Who regulates this medicine and what should prescribers do?

The MHRA is the UK authority responsible for licensing and post‑market surveillance, and prescribers should consult MHRA and NICE for local guidance and safety updates.

Prescribers must report adverse events to the MHRA Yellow Card scheme and follow local formularies when deciding on use.

Regulatory terms
Licensing, post‑market surveillance, ATC classification (C10AX15).

Post‑prescription governance checklist

  • Document indication, baseline tests, monitoring plan and informed consent.
  • Audit prescribing periodically and submit Yellow Card reports for serious or unexpected adverse events.

Storage and handling — UK household and pharmacy guidance

How should patients keep their tablets at home in a damp, cool UK climate?

Store bempedoic acid at room temperature and protect from moisture by keeping tablets in the original packaging.

Avoid storing medication in bathrooms or other humid areas and choose a cool, dry place such as a bedroom cupboard away from direct heat.

When travelling, protect tablets from extreme heat and freezing.

Pharmacy handling

Pharmacies should manage stock rotation, keep storage logs and inspect packaging for integrity on receipt.

Do Don’t
Keep in original blister and box Do not store in bathrooms
Check expiry dates before dispensing Do not expose to excessive heat or moisture
  • Disposal: return unused medicines to any community pharmacy for safe disposal.
  • Keep out of reach of children and pets.

Guidelines for proper use — pharmacist counselling and NHS safety advice

What should the pharmacist cover in a brief counselling session?

Confirm the indication, review concomitant medicines (with attention to gout‑risk and tendon‑risk drugs) and check pregnancy or breastfeeding status.

Explain the main adverse effects to look out for, including raised uric acid, muscle symptoms, gastrointestinal upset and possible liver enzyme changes.

Set the expectation that LDL‑C will be reviewed at 4–12 weeks and agree a monitoring plan.

  • Counselling checklist: allergies, current medicines, renal/hepatic history, gout history, pregnancy status, monitoring plan, when to seek help.

NHS aftercare and safety advice

Provide written aftercare that includes red‑flag symptoms requiring urgent review: severe muscle pain or weakness, signs of tendon rupture (sudden pain, swelling, loss of movement), jaundice or severe abdominal pain.

Advise how to report side effects via the MHRA Yellow Card and give contact points: GP, local pharmacy and lipid clinic where relevant.

Delivery across the United Kingdom

City Region Delivery time
London South East England 9–21 days
Birmingham West Midlands 9–21 days
Manchester North West England 9–21 days
Glasgow Scotland 9–21 days
Leeds Yorkshire and the Humber 9–21 days
Edinburgh Scotland 9–21 days
Bristol South West England 9–21 days
Newcastle North East England 9–21 days
Nottingham East Midlands 9–21 days
Sheffield Yorkshire and the Humber 9–21 days
Belfast Northern Ireland 9–21 days
Cardiff Wales 9–21 days
Plymouth South West England 9–21 days
Aberdeen Scotland 9–21 days